Abstract
The paradigm of empiric treatment for advanced or metastatic non-small cell carcinoma of the lung (A-NSCLC) has been challenged in recent years, with an increasing emphasis on personalizing current therapies and utilizing new therapies that target the drivers of carcinogenesis. As more systemic therapies become available, decisions regarding the optimal type of therapy, timing and duration of treatment are becoming increasingly complex. Clinicians involved in the care of patients with lung cancer may wish to be kept up-to-date regarding the current approaches to treatment. Herein we provide an overview of the current systemic therapies for A-NSCLC, discussing evidence-based approaches to firstline, second-line and maintenance treatment. An outline of the pharmacology of the major classes of active drugs is given, and key evidence is outlined and organized by line of treatment. The characteristics of the target populations for treatment are discussed, along with the optimal combination and timing of therapy.
Keywords: Chemotherapy, bevacizumab, EGFR inhibitors, metastatic, pemetrexed, pharmacology, review, non-small cell carcinoma
Current Respiratory Medicine Reviews
Title: An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Volume: 7 Issue: 5
Author(s): Michael Ong and Mark D. Vincent
Affiliation:
Keywords: Chemotherapy, bevacizumab, EGFR inhibitors, metastatic, pemetrexed, pharmacology, review, non-small cell carcinoma
Abstract: The paradigm of empiric treatment for advanced or metastatic non-small cell carcinoma of the lung (A-NSCLC) has been challenged in recent years, with an increasing emphasis on personalizing current therapies and utilizing new therapies that target the drivers of carcinogenesis. As more systemic therapies become available, decisions regarding the optimal type of therapy, timing and duration of treatment are becoming increasingly complex. Clinicians involved in the care of patients with lung cancer may wish to be kept up-to-date regarding the current approaches to treatment. Herein we provide an overview of the current systemic therapies for A-NSCLC, discussing evidence-based approaches to firstline, second-line and maintenance treatment. An outline of the pharmacology of the major classes of active drugs is given, and key evidence is outlined and organized by line of treatment. The characteristics of the target populations for treatment are discussed, along with the optimal combination and timing of therapy.
Export Options
About this article
Cite this article as:
Ong Michael and D. Vincent Mark, An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189759
DOI https://dx.doi.org/10.2174/157339811797189759 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Medicinal Potential of Heterocyclic Compounds from Diverse Natural Sources for the Management of Cancer
Mini-Reviews in Medicinal Chemistry The Use of PET for Radiotherapy
Current Medical Imaging Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Current Cancer Therapy Reviews A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry Recent Anticancer Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets Preface
Current Radiopharmaceuticals Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels
Current Topics in Medicinal Chemistry Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design